A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide Chemotherapy Versus Carboplatin and Etoposide Alone in Chemotherapy Naive Patients With Extensive-Stage Small Cell Lung Cancer.

Trial Profile

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide Chemotherapy Versus Carboplatin and Etoposide Alone in Chemotherapy Naive Patients With Extensive-Stage Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Palifosfamide (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MATISSE
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 12 Jun 2017 Primary endpoint of overall survival has not been met, according to results published in the Journal of Clinical Oncology.
    • 12 Jun 2017 Results published in the Journal of Clinical Oncology
    • 02 Jun 2015 Status changed from recruiting to discontinued, according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top